The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised


About enEvolv

enEvolv engineers and licenses microorganisms that produce chemicals, enzymes and small molecules for variety of industries. By treating the genome as the unit of engineering, enEvolv offers a substantial advantage in speed, cost, and cellular engineering capabilities.

enEvolv Headquarter Location

83 Cambridge Parkway Unit W806

Cambridge, Massachusetts, 02142,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing enEvolv

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned enEvolv in 1 CB Insights research brief, most recently on Mar 5, 2020.

Expert Collections containing enEvolv

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

enEvolv is included in 1 Expert Collection, including Synthetic Biology.


Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

enEvolv Patents

enEvolv has filed 6 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Molecular genetics
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Biotechnology, Genetics, Transcription factors, Molecular genetics


Application Date


Grant Date



Related Topics

Molecular biology, Biotechnology, Genetics, Transcription factors, Molecular genetics



Latest enEvolv News

Synthetic Biology Global Market Report 2022

Feb 18, 2022

" - I. Du Pont De Nemours and Company, Koninklijke DSM N.V., Codexis, Merck KGaA, Danaher Corporation, EnBiotix, Evonetix, Prokarium, Eurofins Scientific, Origene technologies, Pareto Biotechnologies, Blue heron, Syntrox, ATUM and DNA2.0. The global synthetic biology market is expected to grow from $10.07 billion in 2021 to $13.11 billion in 2022 at a compound annual growth rate (CAGR) of 30.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $33.63 billion in 2026 at a CAGR of 26.6%. The synthetic biology market consists of sales of synthetic compound, technology and related services. Synthetic biology is a field of biology science which involve engineering principles. The main product types of synthetic biology are oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organism.Oligonucleotides are small single-stranded DNA segments that, when internalized by the cell, can specifically suppress the expression of a single protein. The various technologies include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering that are applied in pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others. DNA sequencing is important in development of the synthetic biology in many ways.The DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes.These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the World Economic Forum report in 2019, costs per genome sequenced have been decreased from $3 billion to less than $1,000 over the past 15 years and are projected to be gradually lowered by 10 times over the next five years. The bio-safety risks involved in synthetic biology restrains the synthetic biology market.Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information.With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market.The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc, a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

  • Where is enEvolv's headquarters?

    enEvolv's headquarters is located at 83 Cambridge Parkway, Cambridge.

  • What is enEvolv's latest funding round?

    enEvolv's latest funding round is Acquired.

  • How much did enEvolv raise?

    enEvolv raised a total of $1.7M.

  • Who are enEvolv's competitors?

    Competitors of enEvolv include Synthego.

You May Also Like

eGenesis Logo

eGenesis aims to make available safe and reliable xeno organs, tissues, and cells to patients in need and advance the field of transplantation. eGenesis uses gene-editing tools, such as CRISPR, to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. eGenesis is advancing an initial product toward the clinic for kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy.

Applied StemCell Logo
Applied StemCell

Applied StemCell (ASC) is a biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Using its TARGATT gene modification technology, the company makes site-specific Knockin mouse, rat and human cell line models fast and efficient for pharmaceutical and academic community.


Somagenics specializes in developing innovative technologies that focus on RNA molecules as therapeutic agents and targets as well as biomarkers. Besides the Real-Seq kit family, the company's detection technology platforms also include miR-ID, a novel circularization-based RT-qPCR method for small RNA detection (specifically isomiRs and isoforms), and res-Q, a method for quantifying fragmented RNA from formaldehyde-fixed, paraffin-embedded histology specimens. SomaGenics's therapeutics platform includes development of targets for its proprietary small short hairpin RNA (sshRNA) in wound healing and anti-viral applications.

Synthego Logo

Synthego is a provider of genome engineering solutions. The company's flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego provides precision and automation to genome engineering, to enable rapid and cost-effective research.

Intellia Therapeutics Logo
Intellia Therapeutics

Intellia Therapeutics (NASDAQ: NTLA) is developing genome editing therapies that use CRISPR/Cas9 technology to cure genetic diseases with simple, targeted treatments.

B-MoGen Biotechnologies

B-MoGen Biotechnologies is a genome editing company that has developed methods that employ time-tested genome editing technologies to study human disease and genetics. B-MoGen offers gene-editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.